Nuformix (LON:NFX) Shares Down 10% – Here’s Why

Nuformix plc (LON:NFXGet Free Report)’s share price traded down 10% during mid-day trading on Tuesday . The company traded as low as GBX 0.05 ($0.00) and last traded at GBX 0.05 ($0.00). 417,744 shares changed hands during mid-day trading, a decline of 96% from the average session volume of 10,412,084 shares. The stock had previously closed at GBX 0.05 ($0.00).

Nuformix Stock Performance

The company has a debt-to-equity ratio of 1.17, a current ratio of 1.12 and a quick ratio of 3.35. The firm has a market capitalization of £409,655.00, a PE ratio of -1.63 and a beta of 1.22. The company’s fifty day simple moving average is GBX 0.05 and its 200 day simple moving average is GBX 0.11.

Nuformix Company Profile

(Get Free Report)

Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis.

Read More

Receive News & Ratings for Nuformix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuformix and related companies with MarketBeat.com's FREE daily email newsletter.